NCT01273792

Brief Summary

Susac Syndrome is a rare disease and the establishment of the diagnosis is often difficult. The aim of this investigation is to identify relevant biomarkers and to elucidate the pathogenesis of Susac syndrome

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 6, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 11, 2011

Completed
10.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

July 29, 2021

Status Verified

July 1, 2021

Enrollment Period

11.6 years

First QC Date

January 6, 2011

Last Update Submit

July 28, 2021

Conditions

Susac Syndrome

Outcome Measures

Primary Outcomes (3)

  • disease specific patterns of pathology on cranial MRI

    one-time cranial MRI

  • disease specific patterns of pathology in optical coherence tomography

    one time optical coherence tomography

  • serological biomarkers

    not defined, cross-sectional analysis

Study Arms (2)

Patients with Susac syndrome

Matched healthy controls

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with Susac syndrome (male/female; healthy control subjects

You may qualify if:

  • adult male and female patients with definite Susac syndrome or matching healthy control subjects
  • ability to provide informed consent

You may not qualify if:

  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin

Berlin, 10117, Germany

RECRUITING

Related Publications (1)

  • Dorr J, Radbruch H, Bock M, Wuerfel J, Bruggemann A, Wandinger KP, Zeise D, Pfueller CF, Zipp F, Paul F. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol. 2009 Dec;5(12):683-8. doi: 10.1038/nrneurol.2009.176.

    PMID: 19953118BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples (serum, Blood cells)

MeSH Terms

Conditions

Susac Syndrome

Condition Hierarchy (Ancestors)

Ear DiseasesOtorhinolaryngologic DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurologic ManifestationsRetinal Artery OcclusionRetinal DiseasesEye DiseasesVision DisordersArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesEye ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Jan M Dörr, MD

    NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jan M Dörr, MD

CONTACT

+49 30 450jan-markus.doerr@charite.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PD Dr. med.

Study Record Dates

First Submitted

January 6, 2011

First Posted

January 11, 2011

Study Start

May 1, 2010

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

July 29, 2021

Record last verified: 2021-07

Locations

DE(1)